[Ip-health] Copenhagen: KEI questions The Lancet Taskforce on NCDs and economics on drug pricing & delinkage

Thiru Balasubramaniam thiru at keionline.org
Tue Apr 10 02:08:57 PDT 2018


https://www.keionline.org/27599


Posted on April 10, 2018 <https://www.keionline.org/27599> by Thiru
<https://www.keionline.org/author/thiru>

The World Health Organization (WHO) and the Government of Denmark have
convened a Global Dialogue on Partnerships for Sustainable Financing of
Noncommunicable Disease (NCD) Prevention and Control from 9 April 2018 to
11 April 2018 in Copenhagen. The conference is co-sponsored by the World
Diabetes Foundation, World Economic Forum, NCD Alliance, and IFPMA (Source: WHO
Global Dialogue on Partnerships for Sustainable Financing of
Noncommunicable Disease (NCD) Prevention and Control
<http://www.who.int/global-coordination-mechanism/activities/dialogues/sustainable-finance/en/>
).

On Tuesday, 10 April 2018, a plenary
<http://www.who.int/conferences/global-ncd-conference/financing/Copenhagen-Financing-Dialogue-NCDs-programme.pdf?ua=1>
 was held on Exploring synergies between financing national NCD responses
and broader health systems strengthening efforts for universal health
coverage (UHC) –Launch of the report of the Lancet Taskforce on NCDs and
Economics.

During the question and answer session, James Love (Knowledge Ecology
International), provided the following insights.


   ​1. Prices of insulin, drugs and other technologies for cancer and rare
   diseases, as well as some new promising heart disease treatments, are
   astonishingly high, and access is very unequal.

   2. Outside this room, people don’t think the prices of cancer drugs are
   sustainable.

   3. The UN Secretary General’s High Level Panel on Access to Medicines
   want governments to explore the delinkage of R&D incentives from product
   prices.

   4. Did the Lancet Taskforce on NCDs and economics look at drug pricing
   issues, because I could not find anything in the report about drug prices.

   5. More importantly, did the Lancet Taskforce look at the proposals for
   new business models for financing innovation that delink R&D incentives
   from product prices. Because if you don’t delink incentives from prices,
   access will never be equal.

Dr. Hans Kluge
<http://www.euro.who.int/en/about-us/executive-management/dr-hans-kluge> from
the World Health Organization (WHO) responded to KEI noting that the WHO
Director-General was exploring a new social pact with the pharmaceutical
industry which would involve “sitting down with industry to negotiate a
fair price”.



-- 
Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org


More information about the Ip-health mailing list